New antibody drug treatments for lymphoma

Sam Mayes, Nick Brown, Tim M. Illidge

    Research output: Contribution to journalArticlepeer-review


    Introduction: The advent of anti-CD20 monoclonal antibody (mAb) rituximab heralded a new era in the treatment of non-Hodgkin's lymphoma leading to significant improvements in outcome for patients. This unprecedented success has changed the mindset of the clinical community and catalyzed the interest in the pharmaceutical industry to develop the next-generation of antibodies and antibody conjugates in cancer. Areas covered: There are an ever increasing number of newer generation anti-CD20 and rituximab 'â€̃bio- similars'’ undergoing early phase clinical development. In addition emerging novel therapies including antibody drug conjugates (brentuximab vedotin, SGN-35) and mAb against T-cell lymphomas antigens (e.g., zanolimumab) offer hope of improved outcome for other lymphomas. Bispecific T-cell-engaging antibodies and combination immunotherapy, also provide the promise of further improvements. Radiolabelled antibodies or radioimmunotherapy (RIT) has also demonstrated high clinical activity and two drugs namely 131I-tositumomab (Bexxar) and 90Y-ibritumomab (Zevalin) are licensed. Expert opinion: Despite the large numbers of new anti-CD20 mAb currently undergoing clinical testing, improving on clinical efficacy of rituximab is a substantial challenge. Further improvements in outcome for patients will require rigorous testing in well designed clinical trials alongside the translation of new insights into mechanism of mAb action that lead to improvements in clinical efficacy. © 2011 Informa UK, Ltd.
    Original languageEnglish
    Pages (from-to)623-640
    Number of pages17
    JournalExpert opinion on biological therapy
    Issue number5
    Publication statusPublished - May 2011


    • Anti-CD20
    • immunotherapy
    • lymphoma
    • monoclonal antibodies


    Dive into the research topics of 'New antibody drug treatments for lymphoma'. Together they form a unique fingerprint.

    Cite this